Effective Jan. 1, UTU members taking certain brand-name drugs will be required to pay more for them unless they switch to generic or preferred versions.
Members who choose to stay on the non-formulary/non-preferred drug will be subject to the non-formulary/non-preferred copay.
If you are using one of the drugs noted below, contact your physician and request a prescription for one of the preferred alternatives to avoid paying the higher price.
A mailing will occur on Dec. 1 to members affected by this change.
These formulary changes are made quarterly.
The preferred alternative to Activella (0.5-0.1 mg) is estradiol-norethindrone acet (1-0.5 mg), Prempro or Premphase.
The preferred alternative to Alamast is cromolyn sodium, Patanol or Optivar.
The preferred alternative to Altace is ramipril capsules.
The preferred alternative to Ambien CR is zolpidem tartrate IR (generic Ambien)
The preferred alternative to Cimzia is Humira, Enbrel or Remicade.
The preferred alternative to Ertaczo is econazole nitrate, ketoconazole or nystatin.
The preferred alternative to Lorabid is cefdinir.
The preferred alternative to Ortho Tri-Cyclen Lo is Trinessa, Tri-Previfem or Tri-Sprintec.
The preferred alternative to Quixin is ciprofloxacin, tobramycin sulfate, Zymar, Vigamox or Iquix.
The preferred alternative to Retin-A Micro is tretinoin gel.
The preferred alternative to Retin-A Micro Pump is tretinoin gel.
Related News
- Stand with Sister Nydia Sandoval on Monday!
- Union Leadership Meets with New N.S. Trainees in McDonough, Georgia
- CSX Asks to keep Safety Reports out of the Crew Rooms, Injuries are Up, Fatalities Continue, and Transparency is Down
- Semi Crushes Member in Decatur, Ill.
- Long-time Union Ally Mikie Sherrill Runs for New Jersey Governor
- SMART-TD to FAA: Keep Drones Out of Our Rail Yards
- Have a Tip? Share Your News with SMART-TD!
- The Truth From Within: General Chairpersons From CSX Statement on Departure of CEO Joe Hinrichs
- Overtime Relief for Railroaders Introduced in Congress
- Obituary: York Dudley Poole III